BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024
Accesswire
· *The two poster presentations will report -*
· *first combination data from the Phase 1/2a study with BI-1808 in..
Tumor necrosis factor
News and Video Search Results
News coverage
-
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
GlobeNewswire
-
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire
-
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
GlobeNewswire
-
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire
0 shares
1 views
You might like
Tumor necrosis factor media coverage
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
GlobeNewswire
HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage..
-
iOmx Therapeutics to present new data on lead programs and I/O target screening platform at AACR 2024
GlobeNewswire
-
BioInvent Announces a New Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BI-1910, the Company’s Second Anti-TNFR2 Antibody in Combination with KEYTRUDA(R) (Pembrolizumab)
Accesswire
-
Global Cytokine Market Anticipated to Surge, Exhibiting a 7.44% CAGR Through 2028
GlobeNewswire
-
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
GlobeNewswire
Advertisement
More coverage
Global Anterior Uveitis Treatment Market by Treatment Type (Anti-Tumor Necrosis Factor Agents, Corticosteroids, Cycloplegic Agents), Distribution Channel - Forecast 2024-2030
GlobeNewswire
Dublin, March 19, 2024 (GLOBE NEWSWIRE) -- The "Global Anterior Uveitis Treatment Market by Treatment Type (Anti-Tumor Necrosis..
-
Acimtamig Clinical Trial Bispecific Antibodies Market Insight 2029
GlobeNewswire
-
Advanced Infliximab Model Now Available from DoseMe
Business Wire
-
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire
-
Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology (AAD) Annual Meeting
GlobeNewswire